KyleAddisonBeckwithMD

PubMed

• 6 citations
  Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.
  Adam S Kittai, Ying Huang, Kyle A Beckwith, Seema A Bhat, David A Bond, John C Byrd, Daniel Goldstein, Michael R Grever, Cecelia Miller, Kerry A Rogers, Jennifer A Woy...> ;American Journal of Hematology. 2023 Jan 1
• 19 citations
  Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells.
  Priscilla Do, Kyle A. Beckwith, Carolyn Cheney, Minh Tran, Larry Beaver, Brittany G. Griffin, Xiaokui Mo, Yang Liu, Rosa Lapalombella, Erin Hertlein, Natarajan Muthusa...> ;Journal of Immunology. 2019 May 1
• 249 citations
  Ibrutinib treatment improves T cell number and function in CLL patients
  Meixiao Long, Kyle A. Beckwith, Priscilla Do, Bethany L. Mundy, Amber Gordon, Amy Lehman, Kami J. Maddocks, Carolyn Cheney, Jeffrey A. Jones, Joseph M. Flynn, Leslie A...> ;The Journal of Clinical Investigation. 2017 Jul 17
• 333 citations
  Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
  Joseph A. Fraietta, Kyle A. Beckwith, Prachi R. Patel, Marco Ruella, Zhaohui Zheng, David M. Barrett, Simon F. Lacey, J. Joseph Melenhorst, Shannon E. McGettigan, Dani...> ;Blood. 2016 Mar 3
• 52 citations
  Toll-Like Receptors and Dectin-1, a C-Type Lectin Receptor, Trigger Divergent Functions in CNS Macrophages.
  John C. Gensel, Yan Wang, Zhen Guan, Kyle A. Beckwith, Kaitlyn Braun, Ping Wei, Dana M. McTigue, Phillip G. Popovich> ;The Journal of Neuroscience. 2015 Jul 8
• 72 citations
  Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.
  Zachary A. Hing, Rose Mantel, Kyle A. Beckwith, Daphne Guinn, Erich Williams, Lisa L. Smith, Katie L. Williams, Amy J. Johnson, Amy Lehman, John C. Byrd, Jennifer A. W...> ;Blood. 2015 May 14
• 46 citations
  Tetraspanins as therapeutic targets in hematological malignancy: a concise review
  Kyle A. Beckwith, John C. Byrd, Natarajan Muthusamy> ;Frontiers in Physiology. 2015 Mar 23
• 17 citations
  OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells
  Ta-Ming Liu, Yonghua Ling, Jennifer A. Woyach, Kyle A. Beckwith, Yuh Ying Yeh, Erin Hertlein, Xiaoli Zhang, Amy Lehman, Farrukh T. Awan, Jeffrey A. Jones, Leslie A. An...> ;Blood. 2015 Jan 8
• 45 citations
  Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells
  Yiming Zhong, Dalia El-Gamal, Jason A. Dubovsky, Kyle A. Beckwith, Bonnie K. Harrington, Katie Williams, Virginia M. Goettl, Shruti Jha, Xiaokui Mo, Jeffrey A. Jones, ...> ;Leukemia. 2014 May 1
• 30 citations
  The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model
  Kyle A. Beckwith, Frank Frissora, Matthew R. Stefanovski, William H. Towns, Carolyn Cheney, Xiaokui Mo, Jutta Deckert, Carlo M. Croce, Joseph M. Flynn, Leslie A. Andri...> ;Leukemia. 2014 Jan 21
• 593 citations
  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
  Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Jennifer A. Woyach, Samantha Jaglowski, Yiming Zhong, Joshua Hessler, Ta-Ming Liu, Betty Y. Chang, Karilyn Lar...> ;Blood. 2013 Oct 10
• 46 citations
  Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.
  Erin Hertlein, Kyle A. Beckwith, Gerard Lozanski, Timothy L. Chen, William H. Towns, Amy J. Johnson, Amy Lehman, Amy S. Ruppert, Brad Bolon, Leslie A. Andritsos, Arlet...> ;Plos One. 2013 Oct 9
• Join now to see all